TP53 and acute myeloid leukemia: The p53LSC signature performed well as a predictor of survival, including in sAML patients, as compared to the previously published LSC17 score31 and p53-mutant score generated using all TP53-mutant HSPC rather than LSCs (Extended Data Fig. 6f,g and Supplementary Table 4), providing a powerful tool to aid risk stratification in AML.